The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.
Patrick G. LePore net worth and biography

Patrick LePore Biography and Net Worth

Director of VYNE Therapeutics
Patrick G. LePore is a businessperson who has been at the head of 6 different companies and currently holds the position of Independent Non-Executive Chairman at Lannett Co., Inc., Chairman at Lautus Pharmaceuticals LLC and Chairman at Endo Generics Holdings, Inc. He is also on the board of Matinas BioPharma Holdings, Inc., Villanova University, Tyme, Inc. and VYNE Therapeutics, Inc.

In his past career Patrick G. LePore occupied the position of Chairman for AgeneBio, Inc., President-Healthcare Marketing Group at Cardinal Health, Inc. and Chairman, President & Chief Executive Officer at Boron, LePore & Associates, Inc. (a subsidiary of Cardinal Health, Inc.) and Chairman, President & Chief Executive Officer of Par Pharmaceutical, Inc.

Patrick G. LePore received an undergraduate degree from Villanova University and an MBA from Fairleigh Dickinson University.

What is Patrick G. LePore's net worth?

The estimated net worth of Patrick G. LePore is at least $9,562.50 as of May 26th, 2021. Mr. LePore owns 37,500 shares of VYNE Therapeutics stock worth more than $9,563 as of January 30th. This net worth evaluation does not reflect any other investments that Mr. LePore may own. Learn More about Patrick G. LePore's net worth.

How do I contact Patrick G. LePore?

The corporate mailing address for Mr. LePore and other VYNE Therapeutics executives is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. VYNE Therapeutics can also be reached via phone at (800) 755-7936 and via email at [email protected] Learn More on Patrick G. LePore's contact information.

Has Patrick G. LePore been buying or selling shares of VYNE Therapeutics?

Patrick G. LePore has not been actively trading shares of VYNE Therapeutics within the last three months. Most recently, on Tuesday, November 30th, Patrick G. Lepore bought 12,500 shares of VYNE Therapeutics stock. The stock was acquired at an average cost of $1.02 per share, with a total value of $12,750.00. Learn More on Patrick G. LePore's trading history.

Patrick G. LePore Insider Trading History at VYNE Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2021Buy12,500$1.02$12,750.00View SEC Filing Icon  
8/25/2021Buy12,500$1.60$20,000.00View SEC Filing Icon  
5/26/2021Buy12,500$3.60$45,000.0037,500View SEC Filing Icon  
12/3/2020Buy50,000$1.71$85,500.0050,000View SEC Filing Icon  
See Full Table

Patrick G. LePore Buying and Selling Activity at VYNE Therapeutics

This chart shows Patrick G Lepore's buying and selling at VYNE Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

VYNE Therapeutics Company Overview

VYNE Therapeutics logo
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Read More

Today's Range

Now: $0.26
Low: $0.22
High: $0.26

50 Day Range

MA: $0.20
Low: $0.12
High: $0.28

2 Week Range

Now: $0.26
Low: $0.11
High: $0.79

Volume

486,200 shs

Average Volume

3,639,928 shs

Market Capitalization

$14.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.